Frazier Life Sciences Management, L.P. 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Frazier Life Sciences Management, L.P. disclosed 40 US equity positions worth $3.7bn in its Q4 2025 13F filing. The largest position was NEWAMSTERDAM PHARMA COMPANY at 16.0% of the reported book, followed by MIRM and ARQT. Against the Q3 2025 filing, it opened 5 new positions, added to 6 and reduced 8 among the top 40 holdings.
What did Frazier Life Sciences Management, L.P. own in Q4 2025? Top 40 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | NEWAMSTERDAM PHARMA COMPANY | 16.0% | $594.4m | 16,943,774 | 1% | added | |
| 2 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 14.4% | $536.7m | 6,795,121 | 0% | held |
| 3 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 7.7% | $286.8m | 9,874,511 | 0% | held |
| 4 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 7.3% | $271.2m | 3,545,557 | -8% | reduced |
| 5 | MBX MBX BIOSCIENCES INC | Healthcare | 5.6% | $209.8m | 6,652,013 | 0% | held |
| 6 | PHAT PHATHOM PHARMACEUTICALS INC | 5.6% | $206.8m | 12,466,489 | 0% | held | |
| 7 | MAZE MAZE THERAPEUTICS INC | 5.1% | $189.2m | 4,567,274 | 0% | held | |
| 8 | TRVI TREVI THERAPEUTICS INC | Healthcare | 3.4% | $128.4m | 10,259,409 | 0% | held |
| 9 | KRYS KRYSTAL BIOTECH INC | Healthcare | 3.2% | $120.4m | 488,460 | -29% | reduced |
| 10 | IRON DISC MEDICINE INC | Healthcare | 2.7% | $100.1m | 1,260,000 | -12% | reduced |
| 11 | ERAS ERASCA INC | Healthcare | 2.3% | $84.6m | 22,729,436 | 0% | held |
| 12 | 4XC1 KALVISTA PHARMACEUTICALS INC | 2.2% | $81.4m | 5,039,867 | 0% | held | |
| 13 | PVLA PALVELLA THERAPEUTICS INC NE | 2.0% | $75.6m | 722,400 | 0% | held | |
| 14 | RNAGBP AVIDITY BIOSCIENCES INC | 1.9% | $70.9m | 983,125 | 57% | added | |
| 15 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.7% | $63.5m | 797,455 | -20% | reduced |
| 16 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.7% | $61.7m | 3,153,082 | 16% | added |
| 17 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 1.6% | $59.7m | 728,644 | -38% | reduced |
| 18 | SVRA SAVARA INC | Healthcare | 1.6% | $59.5m | 9,862,301 | -14% | reduced |
| 19 | CYTK CYTOKINETICS INC | Healthcare | 1.6% | $59.4m | 934,642 | 5% | added |
| 20 | ABVX ABIVAX SA | 1.4% | $51.0m | 378,300 | 0% | held | |
| 21 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 1.2% | $43.9m | 4,424,725 | 0% | held |
| 22 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 0.9% | $34.8m | 1,279,754 | 0% | held |
| 23 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 0.9% | $34.6m | 1,297,198 | 111% | added |
| 24 | ZLAB ZAI LAB LTD | Healthcare | 0.9% | $33.6m | 1,902,320 | 17% | added |
| 25 | RAPT RAPT THERAPEUTICS INC | 0.9% | $33.3m | 983,333 | – | new | |
| 26 | VOR VOR BIOPHARMA INC | 0.9% | $33.3m | 2,543,939 | – | new | |
| 27 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.8% | $28.4m | 133,333 | 0% | held |
| 28 | AURA AURA BIOSCIENCES INC | 0.7% | $27.8m | 5,100,000 | 0% | held | |
| 29 | MNKD MANNKIND CORP | Healthcare | 0.6% | $24.0m | 4,225,000 | – | new |
| 30 | VALNEVA SE | 0.5% | $20.2m | 2,291,666 | 0% | held | |
| 31 | ALKS ALKERMES PLC | Healthcare | 0.5% | $19.6m | 700,647 | 0% | held |
| 32 | EOLS EVOLUS INC | Healthcare | 0.5% | $17.5m | 2,630,665 | 0% | held |
| 33 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.4% | $13.4m | 384,782 | 0% | held |
| 34 | NEWAMSTERDAM PHARMA COMPANY | 0.3% | $11.5m | 500,333 | 0% | held | |
| 35 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 0.2% | $9.2m | 241,592 | -38% | reduced |
| 36 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 0.2% | $9.2m | 4,623,324 | 0% | held |
| 37 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 0.1% | $5.3m | 3,868,750 | 0% | held |
| 38 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 0.1% | $4.9m | 521,000 | -73% | reduced |
| 39 | XLO XILIO THERAPEUTICS INC | 0.1% | $3.8m | 5,915,091 | – | new | |
| 40 | IBIO IBIO INC | 0.1% | $3.8m | 1,953,467 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.